Literature DB >> 16960397

Kallmann syndrome phenotype in a female patient with CHARGE syndrome and CHD7 mutation.

Tsutomu Ogata1, Ikuma Fujiwara, Eishin Ogawa, Naoko Sato, Toru Udaka, Kenjiro Kosaki.   

Abstract

We report on a 14 7/12-year-old Japanese female patient with CHARGE syndrome and CHD7 mutation who also exhibited Kallmann syndrome (KS) phenotype. She had poor pubertal development and apparently impaired sense of smell. A GnRH test showed severely compromised responses of LH (<0.5 --> <0.5 IU/L) and FSH (<0.5 --> 1.2 IU/L), and magnetic resonance imaging delineated hypoplastic olfactory bulbs. Mutation analysis revealed a heterozygous nonsense mutation at exon 33 of CHD7 (7027C>T, Q2343X). The results provide further support for the notion that KS phenotype can be included in the phenotypic spectrum of CHARGE syndrome, and indicate that CHARGE syndrome with KS phenotype is caused by a CHD7 mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960397     DOI: 10.1507/endocrj.k06-099

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  18 in total

1.  Identification of two novel missense mutations in the KAL1 gene in Han Chinese subjects with Kallmann Syndrome.

Authors:  T-S Jap; C-Y Chiu; J-F Lirng; G-S Won
Journal:  J Endocrinol Invest       Date:  2010-06-04       Impact factor: 4.256

Review 2.  Chromodomain proteins in development: lessons from CHARGE syndrome.

Authors:  W S Layman; E A Hurd; D M Martin
Journal:  Clin Genet       Date:  2010-04-08       Impact factor: 4.438

3.  The indirect role of fibroblast growth factor-8 in defining neurogenic niches of the olfactory/GnRH systems.

Authors:  Paolo Emanuele Forni; Kapil Bharti; Ellen M Flannery; Tomomi Shimogori; Susan Wray
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

Review 4.  Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome.

Authors:  Gabriel E Zentner; Wanda S Layman; Donna M Martin; Peter C Scacheri
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

Review 5.  The role of CHD7 and the newly identified WDR11 gene in patients with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome.

Authors:  Hyung-Goo Kim; Lawrence C Layman
Journal:  Mol Cell Endocrinol       Date:  2011-08-02       Impact factor: 4.102

6.  Kallmann syndrome.

Authors:  Catherine Dodé; Jean-Pierre Hardelin
Journal:  Eur J Hum Genet       Date:  2008-11-05       Impact factor: 4.246

7.  CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression.

Authors:  Michael P Schnetz; Lusy Handoko; Batool Akhtar-Zaidi; Cynthia F Bartels; C Filipe Pereira; Amanda G Fisher; David J Adams; Paul Flicek; Gregory E Crawford; Thomas Laframboise; Paul Tesar; Chia-Lin Wei; Peter C Scacheri
Journal:  PLoS Genet       Date:  2010-07-15       Impact factor: 5.917

8.  Defects in neural stem cell proliferation and olfaction in Chd7 deficient mice indicate a mechanism for hyposmia in human CHARGE syndrome.

Authors:  W S Layman; D P McEwen; L A Beyer; S R Lalani; S D Fernbach; E Oh; A Swaroop; C C Hegg; Y Raphael; J R Martens; D M Martin
Journal:  Hum Mol Genet       Date:  2009-03-11       Impact factor: 6.150

9.  CHD7, the gene mutated in CHARGE syndrome, regulates genes involved in neural crest cell guidance.

Authors:  Yvonne Schulz; Peter Wehner; Lennart Opitz; Gabriela Salinas-Riester; Ernie M H F Bongers; Conny M A van Ravenswaaij-Arts; Josephine Wincent; Jacqueline Schoumans; Jürgen Kohlhase; Annette Borchers; Silke Pauli
Journal:  Hum Genet       Date:  2014-04-13       Impact factor: 4.132

10.  Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome.

Authors:  Hyung-Goo Kim; Ingo Kurth; Fei Lan; Irene Meliciani; Wolfgang Wenzel; Soo Hyun Eom; Gil Bu Kang; Georg Rosenberger; Mustafa Tekin; Metin Ozata; David P Bick; Richard J Sherins; Steven L Walker; Yang Shi; James F Gusella; Lawrence C Layman
Journal:  Am J Hum Genet       Date:  2008-10-02       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.